Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

One drop before the laser: could this simple step save your sight?

NCT ID NCT07729189

Disease control Sponsor: CMH Multan Institute of Medical Sciences Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 27, 2026 · Last updated Jul 28, 2026 · Updated 1 time

Summary

This trial tests whether a single drop of timolol maleate, given just before Nd:YAG laser capsulotomy, can prevent a short-term rise in eye pressure. The study includes adults who developed clouding of the lens capsule months after cataract surgery. Half receive the timolol drop; the other half receive standard care. Eye pressure is measured before and one hour after the laser to see if the drop makes a difference.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a single drop of 0.5% timolol maleate eye solution given just before laser surgery
What this could lead to
If it works, a single drop before laser treatment could become a simple, low-cost way to protect eyes from pressure spikes.
What could go wrong
This is a small, early-stage trial. The benefit may be small or not apply to all patients. Timolol can cause side effects like eye irritation or slowed heart rate.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

210 people

The number who actually took part.

Started

Mar 2025

Finished

Sep 2025

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged 18-65 years * Male or female participants * Diagnosed with posterior capsule opacification after cataract surgery * Posterior capsule opacification present for at least 3 months * Scheduled to undergo Nd:YAG laser posterior capsulotomy Exclusion Criteria: * History or documented diagnosis of glaucoma * Baseline intraocular pressure greater than 21 mmHg before the procedure

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Capsule opacification are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Capsule Opacification cataract ocular hypertension prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Capsule opacification Ocular hypertension

Contacts and locations

Locations

  • CMH Institute of Medical Sciences

    Multan, Punjab Province, 66000, Pakistan

More trials for these conditions

Other studies related to the condition(s) this trial covers.